$488 Million is the total value of Bellevue Group AG's 122 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 10.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SYK | Sell | STRYKER CORP | $18,618,000 | -11.5% | 155,400 | -14.0% | 3.81% | +0.3% |
| BIIB | Sell | BIOGEN INC | $13,895,000 | -18.6% | 49,000 | -10.1% | 2.84% | -7.7% |
| BSX | Sell | BOSTON SCIENTIFIC CORP | $11,896,000 | -13.1% | 550,000 | -4.3% | 2.44% | -1.5% |
| REGN | Sell | REGENERON PHARMACEUTICALS | $11,857,000 | -22.4% | 32,300 | -15.0% | 2.43% | -12.0% |
| HOLX | Sell | HOLOGIC INC | $8,810,000 | -6.3% | 219,600 | -9.3% | 1.80% | +6.2% |
| ILMN | Sell | ILLUMINA INC | $6,889,000 | -59.9% | 53,800 | -43.1% | 1.41% | -54.5% |
| BDX | Sell | BECTON DICKINSON & CO | $6,622,000 | -33.0% | 40,000 | -27.3% | 1.36% | -24.1% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $5,967,000 | -19.5% | 81,000 | -4.7% | 1.22% | -8.7% |
| ISRG | Sell | INTUITIVE SURGICAL INC | $5,708,000 | -34.4% | 9,000 | -25.0% | 1.17% | -25.6% |
| ABMD | Sell | ABIOMED INC | $5,076,000 | -28.8% | 45,050 | -18.8% | 1.04% | -19.3% |
| CI | Sell | CIGNA CORPORATION | $5,032,000 | -35.3% | 37,722 | -36.8% | 1.03% | -26.7% |
| CHRS | Sell | COHERUS BIOSCIENCES INC | $4,926,000 | -8.9% | 175,000 | -13.4% | 1.01% | +3.3% |
| ARIA | Sell | ARIAD PHARMACEUTICALS INC | $4,665,000 | -31.2% | 375,000 | -24.2% | 0.96% | -22.0% |
| JNJ | Sell | JOHNSON & JOHNSON | $4,378,000 | -25.9% | 38,000 | -24.0% | 0.90% | -15.9% |
| IONS | Sell | IONIS PHARMACEUTICALS INC | $4,353,000 | +10.0% | 91,000 | -15.7% | 0.89% | +24.6% |
| SHPG | Sell | SHIRE PLCsponsored adr | $4,089,000 | -44.6% | 24,000 | -37.0% | 0.84% | -37.3% |
| COO | Sell | COOPER COS INC | $3,499,000 | -16.9% | 20,000 | -14.9% | 0.72% | -5.8% |
| PRGO | Sell | PERRIGO CO PLC | $2,414,000 | -38.8% | 29,000 | -32.1% | 0.49% | -30.6% |
| ALKS | Sell | ALKERMES PLC | $2,362,000 | -2.5% | 42,500 | -17.5% | 0.48% | +10.5% |
| NUVA | Sell | NUVASIVE INC | $2,358,000 | -41.0% | 35,000 | -41.7% | 0.48% | -33.2% |
| ENDP | Sell | ENDO INTL PLC | $2,042,000 | -46.7% | 124,000 | -34.7% | 0.42% | -39.6% |
| MASI | Sell | MASIMO | $2,022,000 | -51.4% | 30,000 | -57.1% | 0.41% | -44.9% |
| HCA | Sell | HCA HOLDINGS INC | $1,762,000 | -25.3% | 23,800 | -23.7% | 0.36% | -15.3% |
| ANGO | Sell | ANGIODYNAMICS INC | $1,716,000 | -24.7% | 101,700 | -21.8% | 0.35% | -14.8% |
| MRK | Sell | MERCK & CO INC | $1,619,000 | -44.8% | 27,500 | -41.5% | 0.33% | -37.4% |
| XENT | Sell | INTERSECT ENT INC | $1,573,000 | -51.6% | 130,000 | -36.7% | 0.32% | -45.2% |
| RDUS | Sell | RADIUS HEALTH INC | $1,521,000 | -53.9% | 40,000 | -34.4% | 0.31% | -47.8% |
| CAH | Sell | CARDINAL HEALTH INC | $1,439,000 | -83.8% | 20,000 | -82.5% | 0.30% | -81.6% |
| IBB | Sell | ISHARES TRnasdq biotec etf | $1,062,000 | -72.8% | 4,000 | -70.4% | 0.22% | -69.3% |
| ICPT | Sell | INTERCEPT PHARMACEUTICALS IN | $924,000 | -58.4% | 8,500 | -37.0% | 0.19% | -52.9% |
| CLVS | Sell | CLOVIS ONCOLOGY INC | $888,000 | -42.7% | 20,000 | -53.5% | 0.18% | -35.0% |
| EVHC | Sell | ENVISION HEALTHCARE HLDGS INC | $824,000 | -5.2% | 13,026 | -66.6% | 0.17% | +7.6% |
| BIB | Sell | PROSHARES TR | $818,000 | -62.9% | 20,500 | -54.9% | 0.17% | -57.8% |
| TBPH | Sell | THERAVANCE BIOPHARMA INC | $492,000 | -26.3% | 15,428 | -16.3% | 0.10% | -16.5% |
| HZNP | Sell | HORIZON PHARMA PLC | $388,000 | -81.7% | 24,000 | -79.5% | 0.08% | -79.4% |
| WMGI | Sell | WRIGHT MED GROUP NV | $230,000 | -86.7% | 10,000 | -85.8% | 0.05% | -84.9% |
| QHCCQ | Exit | Quorum Health Corp | $0 | – | -12,500 | -100.0% | -0.01% | – |
| TMH | Exit | Team Health Holdings Inc. | $0 | – | -25,000 | -100.0% | -0.15% | – |
| IPXL | Exit | Impax Laboratories, Inc. | $0 | – | -95,000 | -100.0% | -0.41% | – |
| AMSG | Exit | Amsurg Corp | $0 | – | -71,400 | -100.0% | -0.86% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bellevue Asset Management AG #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IONIS PHARMACEUTICALS INC | 31 | Q3 2023 | 9.3% |
| Vertex Pharmaceuticals Incorporated | 31 | Q3 2023 | 5.9% |
| NEUROCRINE BIOSCIENCES INC | 31 | Q3 2023 | 5.7% |
| Incyte Corporation | 31 | Q3 2023 | 5.4% |
| INTUITIVE SURGICAL INC | 31 | Q3 2023 | 4.7% |
| ABBOTT LABS | 31 | Q3 2023 | 4.6% |
| ELEVANCE HEALTH INC | 31 | Q3 2023 | 4.3% |
| UnitedHealth Group Incorporated | 31 | Q3 2023 | 3.6% |
| ALNYLAM PHARMACEUTICALS INC | 31 | Q3 2023 | 3.7% |
| Boston Scientific Corporation | 31 | Q3 2023 | 2.5% |
View Bellevue Group AG's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
View Bellevue Group AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.